Logo

OABIW

OmniAb, Inc.

OABIW

OmniAb, Inc. • NASDAQ
$0.13 ▲ 0.00% (+0.13)
Market Cap $153.44 M
52w High $0.17
52w Low $0.13
Dividend Yield 0%
P/E 0
Volume 0
Outstanding Shares 1.20B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.239M ▼ $15.719M ▼ $-16.525M ▼ -738.053% ▼ $-0.14 ▲ $-10.709M ▲
Q2-2025 $3.897M ▼ $19.854M ▼ $-15.875M ▲ -407.365% ▲ $-0.15 ▲ $-14.57M ▼
Q1-2025 $4.154M ▼ $22.998M ▼ $-18.2M ▼ -438.132% ▼ $-0.17 ▼ $-14.101M ▼
Q4-2024 $10.804M ▲ $26.684M ▲ $-13.068M ▲ -120.955% ▲ $-0.12 ▲ $-8.274M ▲
Q3-2024 $4.172M $23.936M $-16.373M -392.45% $-0.16 $-14.837M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $59.5M ▲ $309.69M ▲ $32.246M ▼ $277.444M ▲
Q2-2025 $41.615M ▼ $295.674M ▼ $33.61M ▲ $262.064M ▼
Q1-2025 $43.595M ▼ $306.182M ▼ $32.666M ▼ $273.516M ▼
Q4-2024 $59.434M ▲ $325.558M ▼ $37.94M ▼ $287.618M ▼
Q3-2024 $59.381M $331.554M $39.826M $291.728M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-16.525M ▼ $-9.763M ▼ $-7.665M ▼ $27.684M ▲ $10.256M ▲ $-9.945M ▼
Q2-2025 $-15.875M ▲ $-5.146M ▲ $12.299M ▲ $236K ▲ $7.389M ▲ $-5.311M ▲
Q1-2025 $-18.2M ▼ $-15.872M ▼ $-878K ▼ $44K ▼ $-16.706M ▼ $-16.081M ▼
Q4-2024 $-13.068M ▲ $-3.872M ▲ $385K ▼ $3.849M ▼ $362K ▼ $-3.918M ▲
Q3-2024 $-16.373M $-6.578M $4.449M $8.571M $6.442M $-6.73M

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$10.00M ▲$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement OmniAb is still in an early, platform-building phase financially. Revenue remains very small and has not grown meaningfully over the past several years, which is typical for a royalty‑ and milestone‑driven biotech platform before partners’ drugs reach late-stage trials or approval. At the same time, operating expenses are clearly higher than gross profit, leading to consistent operating losses and negative net income each year. Losses have drifted wider rather than narrowing, suggesting the company is still investing heavily in its platform and team without yet seeing a step‑change in commercial scale. In short, this is a loss‑making innovation platform that has not yet converted its technology and partnerships into material top‑line growth.

Balance Sheet

Balance Sheet The balance sheet shows a company with positive equity and a moderate asset base relative to its current business scale, which is a positive sign from a solvency perspective. Debt exists but appears modest versus total assets and equity, indicating leverage is not the main risk. The weaker point is the relatively small cash position, which looks tight compared with ongoing losses. That combination points to a business that is not overburdened by debt but is likely dependent on either future cash inflows from partners or external financing to comfortably fund operations and R&D over time.

Cash Flow

Cash Flow Cash flow patterns line up with the income statement: cash generated by the business is not yet sufficient to cover operating needs. Operating cash flow has hovered around breakeven in some years but turned more clearly negative most recently, signaling higher cash burn as the company invests. Free cash flow is also negative, though capital spending has been quite light; most of the cash use is tied to operating and R&D costs rather than big equipment or facilities. Overall, OmniAb is a cash‑consuming business at this stage, and its future depends on either growing partner‑related receipts or accessing capital markets when needed.

Competitive Edge

Competitive Edge Competitively, OmniAb is differentiated by its broad, multi‑species transgenic animal platforms and its focus on complex antibody targets, including ion channels and transporters. Few competitors offer this level of species diversity, which can be attractive for partners seeking more options in antibody discovery. Its partnership‑driven model creates a large network of collaborators, including major pharma names, which helps validate the technology and can create recurring, long‑dated revenue streams as programs mature. However, the company still operates in a crowded and rapidly advancing antibody discovery and AI‑enabled drug discovery space, where larger players and emerging platforms compete aggressively. Its moat rests on the uniqueness of its biology, quality of its tools, and depth of partner integrations rather than on current financial scale.

Innovation and R&D

Innovation and R&D Innovation is clearly the centerpiece of OmniAb’s story. The company has built an integrated suite of platforms—multi‑species transgenic animals, a single‑domain antibody chicken system, high‑throughput B‑cell screening, and an AI/ML engine—to cover the full discovery chain. Newer initiatives like the OmniUltra platform and the expansion of OmniDeep and xPloration show that R&D is ongoing and forward‑looking, not static. This innovation focus is a double‑edged sword: it can create powerful long‑term advantages if partners adopt the tools widely and generate successful drugs, but it also requires sustained spending well ahead of revenue and exposes the company to rapid technological change in AI and biologics discovery.

Summary

Overall, OmniAb looks like a classic early‑stage platform biotech: scientifically ambitious, commercially early, and financially dependent on future success of partnered programs and ongoing access to capital. The financials show persistent losses, modest assets and cash, and no clear inflection in revenue yet. On the other hand, the technology stack and partner network suggest meaningful strategic value if the platform continues to gain traction and partners advance more candidates into later stages. Key uncertainties include the pace at which partner programs progress, the adoption of newer tools like OmniUltra and xPloration, and the company’s ability to manage cash burn while continuing to innovate in a competitive and fast‑moving field.